Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Thomas, George V, Tran, Chris, Mellinghoff, Ingo K, Welsbie, Derek S, Chan, Emily, Fueger, Barbara, Czernin, Johannes, Sawyers, Charles L·2006·Nature Medicine

DOI 10.1038/nm1337

Cited by (605)

Items 101–200 of 605

Potential Role of Sugar Transporters in Cancer and Their Relationship with Anticancer Therapy
Moisés Blanco, Angélica Figueroa, Enrique Grande Pulido, Rosario García Campelo, Luís Antón Aparicio · 2010 · International Journal of Endocrinology
RETRACTED ARTICLE: Vasculogenic mimicry formation in EBV-associated epithelial malignancies
Xiang, Tong, Lin, Yu-Xin, Ma, Wenlong, Zhang, Hao-Jiong, Chen, Ke-Ming, He, Gui-Ping, Zhang, Xiao, Xu, Miao, Feng, Qi-Sheng, Chen, Ming-Yuan et al. · 2018 · Nature Communications · Retracted
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model
Sven Arke Lang, Andreas K.A. Gaumann, Gudrun E. Koehl, Ulrike Seidel, Frauke Bataille, Dagmar Klein, Lee M. Ellis, Ulrich Bolder, Ferdinand Hofstaedter, Hans Jürgen Schlitt et al. · 2007 · International Journal of Cancer
The Nutrient-Sensing Hexosamine Biosynthetic Pathway as the Hub of Cancer Metabolic Rewiring
Ferdinando Chiaradonna, Francesca Ricciardiello, Roberta Palorini · 2018 · Cells
Regulation and Function of Protein Kinases and Phosphatases
Heung-Chin Cheng, R. Qi, H. Paudel, Hong-Jian Zhu · 2011 · Enzyme Research
Molecular Diagnosis and Therapy of Kidney Cancer
William Marston Linehan, Gennady Bratslavsky, Peter A. Pinto, Laura S. Schmidt, Len Neckers, Donald Paul Bottaro, Ramaprasad Srinivasan · 2010 · Annual Review of Medicine
Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy
Giovanni Melillo · 2006 · Molecular Cancer Research
Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma
Premal H. Patel, Rajendrakumar S.V. Chadalavada, R.S.K. Chaganti, Robert John Motzer · 2006 · Clinical Cancer Research
State of the Science: An Update on Renal Cell Carcinoma
Eric W. Jonasch, P. Andrew Futreal, Ian J. Davis, Sean T. Bailey, William Y. Kim, James Brugarolas, Amato J. Giaccia, Ghada Kurban, Armin Pause, Judith Frydman et al. · 2012 · Molecular Cancer Research
Transcriptional Control of Cellular Metabolism by mTOR Signaling
Jessica L. Yecies, Brendan D. Manning · 2011 · Cancer Research
SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer
Lianjie Li, Chuan Shen, Eijiro Nakamura, Kiyohiro Ando, Sabina Signoretti, Rameen Beroukhim, Glenn S. Cowley, Patrick Hall Lizotte, Ella Liberzon, Steven Michael Bair et al. · 2013 · Cancer Cell
Biologic Correlation of 2-[18F]-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography in Thymic Epithelial Tumors
Kyoichi Kaira, Masahiro Endo, Masato Abe, Kazuo Nakagawa, Yasuhisa Ohde, Takehiro Okumura, Toshiaki Takahashi, Haruyasu Murakami, Asuka Tsuya, Yukiko Nakamura et al. · 2010 · Journal of Clinical Oncology
Modeling clear cell renal cell carcinoma and therapeutic implications
Melissa M. Wolf, W. Kimryn Rathmell, Kathryn Eby Beckermann · 2020 · Oncogene
The VHL tumor suppressor and HIF: insights from genetic studies in mice
Kapitsinou, P P, Haase, V H · 2008 · Cell Death & Differentiation
Warburg revisited: imaging tumour blood flow and metabolism
Kenneth Alan Miles · 2008 · Cancer Imaging
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
Camillo Porta, Susanne Osanto, Alain Ravaud, Miguel Ángel Climent, Ulka N. Vaishampayan, Dorothy A. White, Patricia A. Creel, Brenda Dickow, Patricia Fischer, Suzanne Gornell et al. · 2011 · European Journal of Cancer
mTORC1 Promotes Metabolic Reprogramming by the Suppression of GSK3-dependent Foxk1 Phosphorylation
He, Long, Gomes, Ana P., Wang, Xin, Yoon, Sang Oh, Lee, Gina, Nagiec, Michal J., Cho, Sungyun, Chavez, Andre, Islam, Tasnia, Yu, Yonghao et al. · 2018 · Molecular Cell
Translational control of gene expression during hypoxia
Twan van den Beucken, Marianne Koritzinsky, Bradly G. Wouters · 2006 · Cancer Biology & Therapy
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
Kim, William Y., Perera, Samanthi, Zhou, Bing, Carretero, Julian, Yeh, Jen Jen, Heathcote, Samuel A., Jackson, Autumn L., Nikolinakos, Petros, Ospina, Beatriz, Naumov, George et al. · 2009 · Journal of Clinical Investigation
Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1α/Sp4
Wen-Bin Tsai, Isamu Aiba, Soo-yong Lee, Lynn G. Feun, Niramol Savaraj, Macus Tien Kuo · 2009 · Molecular Cancer Therapeutics
Hypoxia Inducible Factor Pathway Inhibitors as Anticancer Therapeutics
Burroughs, Sarah K, Kaluz, Stefan, Wang, Danzhu, Wang, Ke, Van Meir, Erwin G, Wang, Binghe · 2013 · Future Medicinal Chemistry
Mechanisms of resistance to anti-angiogenesis therapies
Sandy Giuliano, Gilles Pagès · 2013 · Biochimie
Drug review: Pazopanib
Shingo Miyamoto, Shigenori Kakutani, Yujiro Sato, Akira Hanashi, Yoshitaka Kinoshita, Akira Ishikawa · 2018 · Japanese Journal of Clinical Oncology
Toward rapamycin analog (rapalog)-based precision cancer therapy
Ling-Hua Meng, X. F. Steven Zheng · 2015 · Acta Pharmacologica Sinica
The strange case of AMPK and cancer: Dr Jekyll or Mr Hyde?
Diana Vara‐Ciruelos, Fiona M. Russell, David Grahame Hardie · 2019 · Open Biology
Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis
Priscilla F. McAuliffe, Funda Meric‐Bernstam, Gordon Brent Mills, Ana Maria Gonzalez-Angulo · 2010 · Clinical Breast Cancer
Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells
Shuyang Chen, Nianli Sang · 2015 · Journal of Cellular Biochemistry
Involvement of Hypoxia-Inducible Transcription Factors in Polycystic Kidney Disease
Wanja M. Bernhardt, Michael Sean Wiesener, Alexander Weidemann, Roland Schmitt, Wilko Weichert, Philipp Lechler, Valentina Câmpean, Albert C.M. Ong, Carsten Willam, Norbert Gretz et al. · 2007 · American Journal Of Pathology
Genetics and epigenetics of renal cell cancer
Marcella M.L.L. Baldewijns, Iris J.H. van Vlodrop, Leo J. Schouten, Patricia M.M.B. Soetekouw, Adriaan P. De Bruïne A, Manon van Engeland · 2008 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
mTOR inhibitors in the treatment of cancer
Angelica Fasolo, Cristiana Sessa · 2008 · Expert Opinion on Investigational Drugs
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
Emiliano Calvo, Bernard J. Escudier, Robert John Motzer, Stéphane Marie. Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda A, Viktor Grünwald, John A. Thompson, Alain Ravaud et al. · 2011 · European Journal of Cancer
mTOR inhibitors in renal cell carcinoma
Chiara Battelli, Daniel C. Cho · 2011 · Therapy
Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma
Robert John Motzer, Gary R. Hudes, Brendan D. Curti, David F. McDermott, Bernard J. Escudier, Sylvie Négrier, Brigitte Duclos, Laurence Moore, Timothy E. O’Toole, Joseph P Boni et al. · 2007 · Journal of Clinical Oncology
Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer
Jiayi Zhang, Mingxuan Yao, Shiting Xia, Fancai Zeng, Qiuyu Liu · 2025 · Cellular & Molecular Biology Letters
Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
Terence O’Reilly, Paul M.J. McSheehy · 2010 · Translational Oncology
mTOR, Cancer and Transplantation
Edward Kenneth Geissler, Hans Jürgen Schlitt, George Thomas · 2008 · American Journal of Transplantation
A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis
Boris Shor, Weiguo Zhang, Lourdes Toral‐Barza, Jessica Lucas, Robert T. Abraham, James J. Gibbons, Ker Yu · 2008 · Cancer Research
Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia
Alberto Maria Martelli, Camilla Evangelisti, Francesca Chiarini, Cecilia Grimaldi, Lucia Manzoli, James Andrew McCubrey · 2009 · Expert Opinion on Investigational Drugs
Treatment of kidney cancer
William G. Kaelin · 2009 · Cancer
B55β-Associated PP2A Complex Controls PDK1-Directed Myc Signaling and Modulates Rapamycin Sensitivity in Colorectal Cancer
Jing Ying Tan, Puay Leng Lee, Zhimei Li, Xia Jiang, Yaw Chyn Lim, Shing Chuan Hooi, Qiang Yu · 2010 · Cancer Cell
mTOR Inhibitors in Advanced Renal Cell Carcinoma
Martin Henner Voss, Ana M. Molina, Robert John Motzer · 2011 · Hematology/Oncology Clinics of North America
Hypoxia, drug therapy and toxicity
KangAe Lee, Robert A. Roth, John J. LaPres · 2006 · Pharmacology & Therapeutics
Current and future systemic treatments for renal cell carcinoma
Rosalie Anne Fisher, Martin Eric Gore, James Larkin · 2012 · Seminars in Cancer Biology
TOR signaling never gets old: Aging, longevity and TORC1 activity
Daniel S. Evans, Pankaj Kapahi, Wen‐Chi Hsueh, Lutz Kockel · 2010 · Ageing Research Reviews
Nephrotoxicity of recent anti-cancer agents
Norbert Hendrik Lameire · 2013 · Clinical Kidney Journal
[18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy
Wen Wee Ma, Heather A. Jacene, Dongweon Song, Felip Vilardell, Wells A. Messersmith, Dan A. Laheru, Richard L. Wahl, Chris Endres, Antonio Jimeno, Martin G. Pomper et al. · 2009 · Journal of Clinical Oncology
Combinatorial therapy in tumor microenvironment: Where do we stand?
Smita Kumari, Dia Advani, Sudhanshu Sharma, Rashmi K. Ambasta, Pravir Kumar · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Micromanaging aerobic respiration and glycolysis in cancer cells
Ayla Orang, Janni Petersen, Ross Allan McKinnon, Michael Michael · 2019 · Molecular Metabolism
Hedgehog Signaling Regulates Brain Tumor-Initiating Cell Proliferation and Portends Shorter Survival for Patients with PTEN-Coexpressing Glioblastomas
Qijin Xu, Xiangpeng Yuan, Gentao Liu, Keith L. Black, John S. Yu · 2008 · Stem Cells
mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
Christophe Le Tourneau, Sandrine J. Faivre, Maria Serova, Éric Raymond · 2008 · British Journal of Cancer
Sirolimus effects on cancer incidence after kidney transplantation: a meta‐analysis
Elizabeth L. Yanik, Kulsoom Siddiqui, Eric A. Engels · 2015 · Cancer Medicine
PI3K inhibitors for cancer treatment: where do we stand?
Sauveur-Michel Maira, Frédéric Stauffer, Christian Schnell, Carlos Garcı́a-Echeverrı́a · 2009 · Biochemical Society Transactions
Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells
Zhe Wang, Ming Yue Li, Zhi Hong Zhang, Hong Xiang Zuo, Jing Ying Wang, Yue Xing, MyongHak Ri, Hong Lan Jin, Cheng Hua Jin, Guang Hua Xu et al. · 2020 · Pharmacological Research
The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition
Hutt, Darren M., Roth, Daniela Martino, Vignaud, Hélène, Cullin, Christophe, Bouchecareilh, Marion · 2014 · PLoS ONE
Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer
Philipp C. Manegold, Carmen Paringer, Ulrike Kulka, Klaus Krimmel, Martin Eichhorn, Ralf Wilkowski, Karl‐Walter Jauch, Markus Otto Guba, Christiane J. Bruns · 2008 · Clinical Cancer Research
Targeting mTOR in renal cell carcinoma
Gary R. Hudes · 2009 · Cancer
Targeting LKB1 signaling in cancer
Susanne E. Korsse, Maikel Petrus Peppelenbosch, Wendy van Veelen · 2012 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence
Nasser Hashemi Goradel, Mohammad Hossein Asghari, Milad Moloudizargari, Babak Negahdari, Hamed Haghi‐Aminjan, Mohammad Reza Abdollahi · 2017 · Toxicology and Applied Pharmacology
The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer
Daniel Cho, Sabina Signoretti, Meredith M. Regan, James Walter Mier, Michael B. Atkins · 2007 · Clinical Cancer Research
Synthetic lethality: a framework for the development of wiser cancer therapeutics
William G. Kaelin · 2009 · Genome Medicine
mTORC1 signaling and IL‐17 expression: Defining pathways and possible therapeutic targets
Wenkai Ren, Jie Yin, Jielin Duan, Gang Liu, Bie Tan, Guan Yang, Guoyao Wu, Fuller W. Bazer, Yuanyi Peng, Yulong Yin · 2015 · European Journal of Immunology
Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: From the patient's bed to molecular mechanisms
Magdalena Elżbieta Buczek, Bernard J. Escudier, Ewa Bartnik, Cezary A. Szczylik, Anna Malgorzata Czarnecka · 2013 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Loss of Von Hippel–Lindau (VHL) Tumor Suppressor Gene Function: VHL–HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC)
Hyunho Kim, Byoung Yong Shim, Seung‐Ju Lee, Ji Youl Lee, Hyo Jin Lee, In-Ho Kim · 2021 · International Journal of Molecular Sciences
TOR and ageing: a complex pathway for a complex process
Mark A. McCormick, Shih‐Yin Tsai, Brian Keith Kennedy · 2010 · Philosophical Transactions of the Royal Society B Biological Sciences
Clear Cell Renal Cell Carcinoma: From Biology to Treatment
Adam McLain Kase, Daniel J. George, Sundhar Ramalingam · 2023 · Cancers
Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas
Do‐Youn Oh, Tae‐Won Kim, Young Suk Park, Sang Joon Shin, Seong Hoon Shin, Eun‐Kee Song, Hyo Jin Lee, Kewn‐wook Lee, Yung‐Jue Bang · 2012 · Cancer
NF-κB–Dependent Plasticity of the Epithelial to Mesenchymal Transition Induced by Von Hippel-Lindau Inactivation in Renal Cell Carcinomas
Allan J. Pantuck, Jiabin An, Huiren Liu, Matthew B. Rettig · 2010 · Cancer Research
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma
Matteo Santoni, Ugo De Giorgi, Roberto Iacovelli, Alessandro Conti, Luciano Burattini, L Rossi, Salvatore Luca Burgio, Rossana Berardi, Giovanni Muzzonigro, Enrico Cortesi et al. · 2013 · British Journal of Cancer
A Dialogue between the Hypoxia-Inducible Factor and the Tumor Microenvironment
Frédéric Dayan, Nathalie M. Mazure, M. Christiane Brahimi-Horn, Jacques Pouysségur · 2008 · Cancer Microenvironment
Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors
Sheri L. Spunt, Stephan A. Grupp, Terry A. Vik, Victor M. Santana, David J. Greenblatt, Jill S. Clancy, Anna Berkenblit, Mizue Krygowski, Revathi Ananthakrishnan, Joseph P Boni et al. · 2011 · Journal of Clinical Oncology
Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF‐1α synthesis, and decreases breast cancer metastasis
Zhonghong Wei, Yunlong Shan, Tao Li, Yuping Liu, Zhijie Zhu, Zhaoguo Liu, Yuanyuan Wu, Wenxing Chen, Aiyun Wang, Yin Lu · 2017 · Molecular Carcinogenesis
Tanshinone IIA Inhibits HIF-1α and VEGF Expression in Breast Cancer Cells via mTOR/p70S6K/RPS6/4E-BP1 Signaling Pathway
Guobing� Li, Changyu Shan, Lei Liu, Ting Zhou, Jing Zhou, Xiaoye Hu, Yibiao Chen, Hongjuan Cui, Ning Gao · 2015 · PLoS ONE · Retracted
Mammalian target of rapamycin as a therapeutic target in oncology
Robert T. Abraham, Christina H. Eng · 2008 · Expert Opinion on Therapeutic Targets
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
Britta Weigelt, Julian Downward · 2012 · Frontiers in Oncology
Hypoxia-mediated cancer stem cell resistance and targeted therapy
Xiaoyu Sun, Xuemei Lv, Yuanyuan Yan, Yanyun Zhao, Rong Ma, Miao He, Minjie Wei · 2020 · Biomedicine & Pharmacotherapy
HIV Protease Inhibitors Decrease VEGF/HIF-1α Expression and Angiogenesis in Glioblastoma Cells
Nabendu Pore, Anjali Gupta, George J. Cerniglia, Amit M. Maity · 2006 · Neoplasia
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
Ana M. Molina, Thomas E. Hutson, James Larkin, Anne M. Gold, Karen Wood, Dave Carter, Robert John Motzer, Marc Dror Michaelson · 2013 · Cancer Chemotherapy and Pharmacology
Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma
Hu, Junhui, Tan, Ping, Ishihara, Moe, Bayley, Nicholas A., Schokrpur, Shiruyeh, Reynoso, Jeremy G., Zhang, Yangjun, Lim, Raymond J., Dumitras, Camelia, Yang, Lu et al. · 2023 · Signal Transduction and Targeted Therapy
Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1α and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia
Jun Yang, Afshan Ahmed, Evon Poon, Nina P. Perusinghe, Alexis de Haven Brandon, Gary Box, Melanie R. Valenti, Suzanne A. Eccles, Kasper M. A. Rouschop, Bradly G. Wouters et al. · 2009 · Molecular and Cellular Biology
Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma
Wei Liu, Helen C. Su, Isabel J. Hildebrandt, Michael E. Phelps, Johannes G. Czernin, Wolfgang Weber · 2008 · Clinical Cancer Research
Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
Peter M. Fischer · 2016 · Medicinal Research Reviews
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
Alain Ravaud, Carlos H. Barrios, B. Yа. Alekseev, M.-H. Tay, Sanjiv S. Agarwala, Şuayib Yalçın, C.-C. Lin, Laslo Roman, Michail I. Shkolnik, Oezlem Anak et al. · 2015 · Annals of Oncology
Melatonin down‐regulates HIF‐1α expression through inhibition of protein translation in prostate cancer cells
Jong‐Wook Park, Mi‐Sun Hwang, Seong‐Il Suh, Won‐Ki Baek · 2009 · Journal of Pineal Research
Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET
Kaiyumars B. Contractor, Eric Ofori Aboagye · 2009 · Journal of Nuclear Medicine
HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer
Autumn L. Jackson, Bing Rong Zhou, William Y. Kim · 2010 · Expert Opinion on Therapeutic Targets
Hyaluronan Production Regulates Metabolic and Cancer Stem-like Properties of Breast Cancer Cells via Hexosamine Biosynthetic Pathway-coupled HIF-1 Signaling
Theerawut Chanmee, Pawared Ontong, Tomomi Izumikawa, Miho Higashide, Nobutoshi Mochizuki, Chatchadawalai Chokchaitaweesuk, Manatsanan Khansai, Kazuki Nakajima, Ikuko Kakizaki, Prachya Kongtawelert et al. · 2016 · Journal of Biological Chemistry
Phosphorescent Ir (III) complexes as cellular staining agents for biomedical molecular imaging
Sana A. Shaikh, Yihan Wang, Fawad Ur Rehman, Hui Jiang, Xuemei Wang · 2020 · Coordination Chemistry Reviews
Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies
Benoît Bilanges, David Stokoe · 2007 · Oncogene
Targeting mTOR pathway: A new concept in cancer therapy
S.H. Advani · 2010 · Indian Journal of Medical and Paediatric Oncology
Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma
Jennifer Woodard, Antonella Sassano, Nissim Hay, Leonidas C. Platanias · 2008 · Clinical Cancer Research
Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma
Myung‐Chul Kim, Zeng Jin, Ryan H. Kolb, Nicholas C. Borcherding, Jonathan Alexander Chatzkel, Sara Moscovita Falzarano, Weizhou Zhang · 2021 · Cancers
Optimal targeting of the mTORC1 kinase in human cancer
Heidi A. Lane, Madlaina Breuleux · 2009 · Current Opinion in Cell Biology
Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma
Virginie Nerich, Marion Hugues, Thierry Nai, Ulrich Stein, Thierry Nguyen Tan Hon, Philippe Montcuquet, Tristan Maurina, Guillaume Mouillet, Marie Justine Paillard, Laetitia Borowski et al. · 2014 · OncoTargets and Therapy
An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor
Yukari Shirai, Christalle C. T. Chow, Gouki Kambe, Tatsuya Suwa, Minoru Kobayashi, Itsuki Takahashi, Hiroshi Harada, Jin‐Min Nam · 2021 · Cancers
Differential Diagnosis of Renal Tumors With Clear Cytoplasm: Clinical Relevance of Renal Tumor Subclassification in the Era of Targeted Therapies and Personalized Medicine
Rajen Goyal, Elizabeth Gersbach, Ximing J. Yang, Stephen M. Rohan · 2013 · Archives of Pathology & Laboratory Medicine
Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Fan Lin, Ping L. Zhang, Ximing J. Yang, Jeffrey W. Prichard, Mingyue Lun, Robert Eldon Brown · 2006 · PubMed
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies
Thomas Elmer Witzig, Scott H. Kaufmann · 2006 · Current Treatment Options in Oncology
Hypoxia-inducible factor 1 and its role in viral carcinogenesis
Sean Cuninghame, Robert Jackson, Ingeborg Zehbe · 2014 · Virology
Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3
Yue Xing, Chunliu Mi, Zhe Wang, Zhi Hong Zhang, Ming Yue Li, Hong Xiang Zuo, Jing Ying Wang, Xuejun Jin, Juan Ma · 2018 · Pharmacological Research
mTOR and cancer: reason for dancing at the crossroads?
GEORGE V. THOMAS · 2005 · Current Opinion in Genetics & Development